Choi Minsig, Kim Richard, Saif Muhammad Wasif
Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
JOP. 2012 Mar 10;13(2):163-5.
Currently gemcitabine-based regimens and FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) are widely used standard for first-line treatment of patients with advanced pancreatic adenocarcinoma. Refractory patients may receive either FOLFOX (5-fluorouracil and oxaliplatin) or gemcitabine based on the first line regimen. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of refractory pancreatic cancer, as these were presented in Abstracts #248 and #373 of the meeting.
目前，基于吉西他滨的治疗方案和FOLFIRINOX（5-氟尿嘧啶、亚叶酸钙、伊立替康和奥沙利铂）是晚期胰腺腺癌患者一线治疗的广泛应用的标准方案。难治性患者可根据一线治疗方案接受FOLFOX（5-氟尿嘧啶和奥沙利铂）或吉西他滨治疗。本综述是对2012年美国临床肿瘤学会（ASCO）胃肠道癌症研讨会的更新，内容涉及难治性胰腺癌治疗的最新进展，这些进展在会议的摘要#248和#373中有所介绍。
